171 results on '"Ballreich, Jeromie"'
Search Results
2. Pediatric Drugs, Accelerated Approval, and Prospects for Reform
3. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States
4. Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial
5. Medicaid Spending and Utilization of Gene and RNA Therapies for Rare Inherited Conditions
6. Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19
7. Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?
8. Mobile health school screening and telemedicine referral to improve access to specialty care in rural Alaska: a cluster- randomised controlled trial
9. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis
10. Cost‐effectiveness analysis of a digital diabetes‐prevention programme versus an in‐person diabetes‐prevention programme in people with prediabetes in the United States.
11. Sociodemograhic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations
12. THE ROLE OF PERSON- AND FAMILY-ORIENTED LONG-TERM SERVICES AND SUPPORTS
13. THE GROWTH OF THE HOME CARE WORKFORCE FROM 2000 TO 2019 AND THE ROLE OF PUBLIC FINANCING
14. The Association Between Drug Approvals and Burden of Disease From 1990 to 2017
15. Modern External Ring Fixation Versus Internal Fixation for Treatment of Severe Open Tibial Fractures: A Randomized Clinical Trial (FIXIT Study)
16. Pediatric Drugs, Accelerated Approval, and Prospects for Reform
17. The Role of Place in Person‐ and Family‐Oriented Long‐Term Services and Supports.
18. Provider and Patient Characteristics of Medicare Beneficiaries Who Are High-Risk for COVID-19 Mortality
19. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry
20. Incorporating Ethics in Policy Change and Health Reform
21. Examining Opportunities to Increase Savings From Medicare Price Negotiations
22. Accelerated approval drug labels often lack information for clinical decision making
23. 19. Cost-Effectiveness of the Technology-Enhanced Community Health Nursing Intervention for Adolescents and Young Adults with Pelvic Inflammatory Disease
24. Factors associated with high short-acting β2-agonist use in urban children with asthma
25. Anticipating Reforms to the Prescription Drug User Fees Act
26. Medicare Spending on Drugs With Accelerated Approval
27. Reducing Branded Prescription Drug Prices: A Review of Policy Options
28. Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019
29. Estimating & comparing greenhouse gas emissions for existing intramuscular COVID-19 vaccines and a novel thermostable oral vaccine
30. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
31. Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic
32. Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
33. Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs
34. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis
35. Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model
36. Biosimilar uptake of filgrastim and impact on spending in Medicare Part D from 2015 to 2019.
37. Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication
38. Consider expenditure controls’ impacts on equity
39. Cost‐effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin‐exacerbated respiratory disease
40. Equitable Access to Care — How the United States Ranks Internationally
41. P478-LB: Cost-Effectiveness of the Technology-Enhanced Community Health Nursing Intervention for Adolescents and Young Adults with Pelvic Inflammatory Disease.
42. Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model.
43. Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019
44. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis
45. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US
46. Affording Genetic Therapies in the Medicaid Program
47. Cost-effectiveness of School Hearing Screening Programs: A Scoping Review
48. Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs
49. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers
50. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.